Marc’s years of combined industry and academic experience are ideally suited to his role at Synapse, which he began in January 2018. During his career, he has helped take multiple products from conception and design through to scientific and regulatory validation, and eventually to patent protection and commercialization.
In the seven years before joining Synapse, Marc worked as a research scientist and project manager for a Charlottetown-based bioscience company. There, he was instrumental in the R&D of novel drug candidates for neuropathic pain as well as the development and commercialization of a line of natural health products targeting neurodegenerative disorders.
During his post-doctoral fellowship at the University of Prince Edward Island, Marc was Project Coordinator for the UPEI-based Atlantic Centre for Bioactive Valuation, focusing on designing and implementing novel assays of stroke for commercial use. He obtained a BSc in Biology from Mount Allison University, followed by an MSc and PhD in Pharmacology from Dalhousie University.